Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment

Journal:

Immunity

Published:

2026-04-02

DOI:

10.1016/j.immuni.2026.03.011

Affiliations:

11

Authors:

14

Go to article

Institutions	Authors	Share
Oregon Health and Science University (OHSU), United States of America (USA)	7.750000	0.55
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA)	2.500000	0.18
Abramson Cancer Center, Penn, United States of America (USA)	2.500000	0.18
Parker Institute for Cancer Immunotherapy, United States of America (USA)	0.750000	0.05
NIH National Institute of General Medical Sciences (NIGMS), United States of America (USA)	0.500000	0.04

Interested in Oncology and Carcinogenesis?